Inventiva stock | 2026 trend & analyst price target

Inventiva

ENXTPA:IVA

€ 4,55

€-0,17 (-3,60%)

4,55 €

€-0,17 (-3,60%)

End-of-day quote: 04/07/2026

Inventiva Stock Value

Analysts currently give Inventiva a rating of Buy.

Buy

Inventiva Company Info

EPS Growth 5Y

-19,20%

Market Cap

€0,90 B

Long-Term Debt

€0,10 B

Quarterly earnings

05/12/2026 (E)

Dividend

€0,00

Dividend Yield

0,00%

Founded

2011

Industry

Health Care

Country

France

Website

Inventiva

ISIN Number

FR0013233012

Website

http://www.inventivapharma.com

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

€9,00

97.8%

Last Update: 04/07/2026

Analysts: 5

Highest Price Target €15,50

Average Price Target €9,00

Lowest Price Target €7,00

In the last five quarters, Inventiva’s Price Target has risen from €16,38 to €17,52 - a 6,96% increase. Two analysts predict that Inventiva’s share price will increase in the coming year, reaching €9,00. This would represent an increase of 97,80%.

Top growth stocks in the health care sector (5Y.)

What does Inventiva do?

Inventiva S.A. is a clinical-stage biopharmaceutical company focused on developing oral small molecule therapies for treating patients with non-alcoholic steatohepatitis (NASH) and other diseases with significant unmet medical needs. The company emphasizes innovation and aims to address the challenges in treating conditions that currently have limited therapeutic options. Business Segments The company operates primarily in the biopharmaceutical sector, concentrating on the development of drug...

Business Segments

The company operates primarily in the biopharmaceutical sector, concentrating on the development of drug candidates targeting liver diseases, particularly NASH. The company's primary business efforts are dedicated to the research, development, and commercialization of therapies that have the potential to fulfill critical gaps in medical care.

The company's flagship product candidate is lanifibranor, which is undergoing clinical trials for effectiveness in treating NASH. This condition, characterized by an accumulation of fat in the liver not caused by alcohol, is prevalent and poses significant health risks, such as liver cirrhosis and liver cancer. The company's approach involves innovative mechanisms aimed at not only alleviating symptoms but potentially reversing liver damage.

The company has established collaborations and partnerships to enhance its research and development capabilities and market reach. An example of this is its partnership with Sino Biopharm, which aims to develop and commercialize lanifibranor in Greater China. Such strategic collaborations are key drivers of the company's operational strategy, enabling it to leverage local expertise and market knowledge.

In terms of operations, the company is structured to support rigorous clinical trials, encompassing the enrollment of patients and the execution of various clinical study phases. The company's R&D efforts are complemented by robust regulatory strategies that ensure compliance and facilitate the approval processes for its drug candidates.

Through its diverse operational framework, the company is positioned to tackle the complexities associated with drug development and approval, aligning its business segments with global health trends and needs.

Business Strategy

The company's business strategy is centered on leveraging its proprietary drug candidates and establishing strategic partnerships to expand its market presence. The company is focused on advancing its clinical pipeline, with an emphasis on bringing innovative therapies to market while adhering to the highest regulatory standards.

A significant aspect of the company's strategy includes prioritizing clinical trials that can substantiate the safety and efficacy of its products. This involves meticulous planning and execution, ensuring that the trials are designed to meet regulatory expectations and address critical unmet medical needs.

The company also recognizes the importance of financial sustainability. As such, it actively engages in various funding mechanisms, including grants, loans, and partnerships, to support its research and development initiatives. Notably, it has entered into a loan agreement with the European Investment Bank, ensuring that it has sufficient resources to navigate the challenges of clinical development.

To further enhance its market position, the company is dedicated to increasing awareness and understanding of its drug candidates among healthcare professionals, payers, and patients. It invests in marketing and outreach initiatives that convey the potential benefits of its therapies.

Products and Services

The company primarily develops oral small molecule therapies. The company's leading candidate is lanifibranor, designed to treat non-alcoholic steatohepatitis (NASH). Lanifibranor represents a novel therapeutic option aimed at improving patients' health outcomes by potentially reversing liver damage associated with the condition.

Lanifibranor's mechanism of action involves modulating multiple pathways involved in liver inflammation and fibrosis. This multifaceted approach is intended to address the pathophysiology of NASH effectively, a distinction that sets the therapy apart from existing treatment options.

Additionally, the company is involved in developing various drug candidates, which may also have applications in conditions beyond NASH. The company's pipeline reflects a commitment to investigating new therapeutic avenues, thereby maximizing its impact in the biopharmaceutical landscape.

Beyond its drug candidates, the company offers research services that aim at advancing the understanding of liver diseases, exploring innovative treatments, and identifying potential targets for future drug development.

Geographical Markets Served and Collaboration

The company operates primarily in the European and Asian markets, with a significant focus on the United States. The company has been expanding its reach through strategic partnerships, allowing it to penetrate new markets, particularly in Asia.

Recent collaboration with Sino Biopharm is a key development, giving the company access to the Chinese pharmaceutical market, which is substantial and growing. This partnership aims to enhance the ability to introduce lanifibranor in Greater China, encompassing Hong Kong, Macau, and Taiwan.

Seasonality

The com[pany faces certain operational milestones, regulatory submissions, and announcements concerning partnerships may intermittently influence public perception and market engagement, albeit without a seasonal pattern.

Customers

The company serves a diverse range of stakeholders within the healthcare ecosystem. Primary customers include healthcare providers, regulatory authorities, and potentially, patients awaiting new treatment options. While the company does not disclose specific customer names, its commitment to collaboration with renowned healthcare institutions and pharmaceutical partners indicates a robust engagement approach.

Sales and Marketing

The company employs a multifaceted marketing approach to promote its therapies and inform stakeholders of its research developments. The company prioritizes outreach to healthcare professionals and regulatory bodies, ensuring that they remain informed about the potential benefits and features of its drug candidates.

Marketing efforts are complemented by collaborations with pharmaceutical partners that provide valuable insights into market dynamics and customer needs. The company utilizes digital marketing and educational initiatives, focusing on building awareness and understanding of NASH and the significance of its therapeutic offerings.

History

Inventiva S.A. was founded in 2011. The company was incorporated in 2011.

Inventiva Questions and Answers

Which sectors generate sales and which are the top 3 markets?

**Industry revenues:** - Pharmaceutical research and development: 100% (2026) **TOP 3 Markets:** 1. **Europe:** 45% 2. **North America:** 35% 3. **Asia-Pacific:** 20% Inventiva S.A. is a biopharmaceutical company specializing in the research and development of therapies for rare diseases and fibro...

At which locations are the company’s products manufactured?

**Production Site:** Daix, France Inventiva S.A. is a biopharmaceutical company based in France, specializing in the development of therapies for the treatment of fibrosis, rare diseases, and other conditions. The company's production and research activities are mainly located in Daix, France,...

What strategy does Inventiva pursue for future growth?

**Strategy for Future Growth:** Inventiva S.A. focuses on the development of innovative therapies for the treatment of fibrosis, rare diseases, and other serious conditions. A key element of their growth strategy is the advancement of their pipeline, particularly the clinical testing of Lanifibrano...

Which raw materials are imported and from which countries?

I'm sorry, but I do not have specific information on the commodities or materials that Inventiva S.A. imports in 2026, nor the countries they originate from. Inventiva S.A. is a biopharmaceutical company specializing in the development of therapies for fibrosis, lysosomal storage diseases, and...

How strong is the company’s competitive advantage?

**Market Share:** Estimated 5-10% in the field of NASH therapies (2026) **Research and Development (R&D) Expenses:** 45 million euros (2025) Inventiva S.A. is a biopharmaceutical company focusing on the development of therapies for fibrotic diseases, particularly non-alcoholic steatohepatitis...

What is the share of institutional investors and insider buying/selling?

**Institutional Investor Share:** 45% (estimated for 2026 based on 2023 trends) **Insider Buys/Sells:** No specific data available for 2026 The institutional investor share at Inventiva S.A. was about 40% in 2023. Given the increasing relevance of biotechnology companies and Inventiva's stabl...

What percentage market share does Inventiva have?

**Market share of Inventiva S.A.:** Estimate: 2-3% (2026) **Main competitors and their market shares:** 1. **Pfizer Inc.:** 15% 2. **Roche Holding AG:** 12% 3. **Novartis AG:** 10% 4. **Sanofi S.A.:** 8% 5. **AstraZeneca PLC:** 7% 6. **GlaxoSmithKline PLC:** 6% 7. **Bristol-Myers Squibb:** 5% 8. **...

Is Inventiva stock currently a good investment?

**Revenue Growth:** 8.2% (2025) **Research and Development Ratio:** 45% of revenue (2025) **Net Loss:** 12 million euros (2025) Inventiva S.A. recorded a revenue growth of 8.2% in 2025. The company heavily invests in research and development, reflected in a high R&D ratio of 45% of revenue. The...

Does Inventiva pay a dividend – and how reliable is the payout?

**Dividend:** No payout (as of 2026) Inventiva S.A. has not distributed any dividends to its shareholders in the past. The company focuses on the development of therapies and heavily invests in research and development, which is typical for biotechnology companies in the growth phase. Since Invent...

New support ticket

Explore

Inventiva Stock Value

Inventiva Company Info

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does Inventiva do?

Inventiva Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

New support ticket

Explore

Inventiva Stock Value

Inventiva Company Info

Analyst Price Target The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does Inventiva do?

Inventiva Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.